Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for the general public in Europe, Middle East and Africa for disease awareness purposes only. Nothing on the site constitutes individual medical advice. Individuals are advised to consult their physician or other appropriate HCP. NP-CEMEA-00178 April 2022.

Video library

Hear from people about their experiences living with hereditary ATTR (hATTR) amyloidosis

Why we need to Bridge the Gap in awareness of hATTR amyloidosis

Jean-Christophe Fidalgo, Amyloidosis Alliance, and Koenraad Verhagen, The Stichting Amyloïdose Nederland, on the value of sharing patients' stories

Experiences of those living with hereditary ATTR (hATTR) amyloidosis

Catilena's Story, Spain

Roland's story, Germany

David's story, U.K.

Jean-Christophe's story, France

Philip's story, the Netherlands

Vitor's story, Portugal

Andreas's story, Sweden

Tips from a cardiac genetic nurse

Talking to family about a diagnosis

Dealing with a diagnosis of hATTR amyloidosis

When a family member is at risk of hATTR amyloidosis

The importance of talking about hATTR amyloidosis